Full Press Release Details
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease.
BIIB
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
Key Takeaway: Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease
Price reaction · baseline $309.6 (2023-05-12 close) · clean, no other BIIB news in the window
day 0 close · peak
+0.7%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis